FRED R. SATTLER, M.D.; MICHAEL R. WEITEKAMP, M.D.; JAMES O. BALLARD, M.D.
Several new beta-lactam antibiotics impair normal hemostasis. Hypoprothrombinemia has occurred frequently with cephalosporins that possess a methylthiotetrazole substitution (cefamandole, moxalactam, and cefoperazone). The incidence ranges from 4% to 68%, and the risk is greatest in debilitated patients with cancer, intra-abdominal infection, or renal failure. Impaired platelet function caused by perturbation of agonist receptors on the platelet surface has occurred primarily with beta-lactam antibiotics having an alphacarboxyl substitution (moxalactam, carbenicillin, and ticarcillin). These antibiotics often cause the template bleeding time to be markedly prolonged (> 20 minutes). Acylureidopenicillins, which lack the alpha-carboxyl marker, impair platelet function less frequently and only modestly prolong the bleeding time. If serious hemorrhage occurs, hypoprothrombinemia associated with methylthiotetrazole-substituted cephalosporins should be treated with fresh frozen plasma. Likewise, dangerous bleeding due to impaired platelet aggregation requires treatment with platelet concentrates.
Learn more about subscription options.
Register Now for a free account.
SATTLER FR, WEITEKAMP MR, BALLARD JO. Potential for Bleeding with the New Beta-Lactam Antibiotics. Ann Intern Med. 1986;105:924–931. doi: 10.7326/0003-4819-105-6-924
Download citation file:
Published: Ann Intern Med. 1986;105(6):924-931.
Coagulopathies, Hematology/Oncology, Nephrology.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only